Axsome Therapeutics (NASDAQ:AXSM) Receives Outperform Rating from William Blair

William Blair reissued their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report sent to investors on Friday,RTT News reports.

A number of other equities research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a research report on Monday, January 13th. Mizuho reduced their price target on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $121.00 target price on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Finally, StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $130.69.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock opened at $103.11 on Friday. The business has a 50-day moving average of $92.64 and a 200 day moving average of $90.03. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $105.00. The stock has a market capitalization of $5.00 billion, a price-to-earnings ratio of -15.79 and a beta of 1.04. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter last year, the company earned ($1.32) EPS. As a group, sell-side analysts forecast that Axsome Therapeutics will post -4.73 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AXSM. Northwestern Mutual Wealth Management Co. acquired a new position in Axsome Therapeutics during the second quarter worth approximately $27,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Axsome Therapeutics in the 2nd quarter valued at approximately $47,000. R Squared Ltd acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $64,000. KBC Group NV raised its stake in shares of Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after purchasing an additional 385 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after purchasing an additional 318 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.